Name: the race to commercialize biotechnology: molecules, market and the state in japan and the us
SKU: 2416287
Price: 438277.00 COP
Availability: InStock
Author: s. collins
ISBN: 9780415283397

portada the race to commercialize biotechnology: molecules, market and the state in japan and the us

the race to commercialize biotechnology: molecules, market and the state in japan and the us

Formato

Libro Físico

Autor

s. collins

Año

2003

N° páginas

208

ISBN

0415283396

ISBN13

9780415283397

Categorías

Japón
Historia de asia

the race to commercialize biotechnology: molecules, market and the state in japan and the us

S. Collins (Autor) · · Libro Físico

Libro Nuevo Importado

Envío: 20 a 24 días háb.

$ 876.554$ 438.277

-50%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan más de 100 unidades

$ 438.277

¡Envío Gratis! Llega entre el 26 Nov y el 03 Dic a Bogota, Cundinamarca. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "the race to commercialize biotechnology: molecules, market and the state in japan and the us"

in the early 1970s the demonstration of recombinant dna offered new possibilities for making drugs and other products. entrepreneurs in the us responded almost immediately, forming dedicated companies to commercialize the new technology. prospective japanese entrepreneurs, however, faced imposing regulatory hurdles and a drug pricing system that deterred entry into pharmaceutical applications. consequently, us entrepreneurs raced ahead, establishing a lead that japan has never been able to fully close. this comparative study looks at the early development of biotechnology in the us and japan. drawing on primary and secondary sources it traces the historical roots of recombinant dna technology, discusses the tensions between regulation and promotional policies and identifies the major actors and strategies that launched biotechnology in both countries. developing several strands of theory in economic history, science and technology policy, the book proposes a simple model that relates the differences in the two countries` response to variations in the availability of institutional, financial and organizational resources needed to commercialize the new technology